Clinical significance of microcytosis in patients with primary myelofibrosis

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1212-1216

  Strati, Paolo ^a   Pemmaraju, Naveen ^a   Estrov, Zeev ^a   Cardenas Turanzas, Marylou ^a   Pierce, Sherry ^a   Newberry, Kate J ^a   Daver, Naval ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Iron homeostasis; Leukemia; Microcytosis; Primary myelofibrosis; Transferrin saturation

Indexed keywords

IRON; TRANSFERRIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MEDICAL RECORD REVIEW; MICROCYTOSIS; MYELOID METAPLASIA; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SPLENOMEGALY; TRANSFERRIN SATURATION; DISEASE FREE SURVIVAL; ERYTHROCYTE; IRON HOMEOSTASIS; LEUKEMIA; MEAN CORPUSCULAR VOLUME; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

IRON HOMEOSTASIS; LEUKEMIA; MICROCYTOSIS; PRIMARY MYELOFIBROSIS; TRANSFERRIN SATURATION;

AGED; DISEASE-FREE SURVIVAL; ERYTHROCYTE INDICES; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES;

EID: 84907990233     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.08.007     Document Type: Article

References (26)

1. Tefferi A., Lasho T.L., Jimma T., Finke C.M., Gangat N., Vaidya R., et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc 2012, 87:25-33.
2. Abdel-Wahab O.I., Levine R.L. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med 2009, 60:233-245.
3. Tefferi A., Dingli D., Li C.Y., Mesa R.A. Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates. Leuk Res 2006, 30:677-680.
4. Camaschella C., Strati P. Recent advances in iron metabolism and related disorders. Intern Emerg Med 2010, 5:393-400.
5. Kassebaum N.J., Jasrasaria R., Naghavi M., Wulf S.K., Johns N., Lozano R., et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood 2014, 123:615-624.
6. Mughal T.I., Vaddi K., Sarlis N.J., Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 2014, 7:89-101.
7. Pardanani A., Finke C., Abdelrahman R.A., Lasho T.L., Tefferi A. Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis. Am J Hematol 2013, 88:312-316.
8. Tefferi A., Vaidya R., Caramazza D., Finke C., Lasho T., Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol: Off J Am Soc Clin Oncol 2011, 29:1356-1363.
9. Verstovsek S., Kantarjian H., Mesa R.A., Pardanani A.D., Cortes-Franco J., Thomas D.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
10. Cohen A.R., Galanello R., Pennell D.J., Cunningham M.J., Vichinsky E. Thalassemia. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program 2004, 14-34.
11. Steensma D.P., Gibbons R.J., Higgs D.R. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005, 105:443-452.
12. Ballas S.K., Krasnow S.H. Balanced globin synthesis in idiopathic myelofibrosis. Clin Chim Acta Int J Clin Chem 1981, 110:255-259.
13. Veer A., Kosciolek B.A., Bauman A.W., Rowley P.T. Acquired hemoglobin H disease in idiopathic myelofibrosis. Am J Hematol 1979, 6:199-206.
14. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
15. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115:1703-1708.
16. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol: Off J Am Soc Clin Oncol 2011, 29:392-397.
17. Caramazza D., Begna K.H., Gangat N., Vaidya R., Siragusa S., Van Dyke D.L., et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011, 25:82-88.
18. Tarkun P., Mehtap O., Atesoglu E.B., Geduk A., Musul M.M., Hacihanefioglu A. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol 2013, 91:228-235.
19. De Falco L., Sanchez M., Silvestri L., Kannengiesser C., Muckenthaler M.U., Iolascon A., et al. Iron refractory iron deficiency anemia. Haematologica 2013, 98:845-853.
20. Camaschella C., Silvestri L. Molecular mechanisms regulating hepcidin revealed by hepcidin disorders. Sci World J 2011, 11:1357-1366.
21. Hentze M.W., Muckenthaler M.U., Galy B., Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell 2010, 142:24-38.
22. Ferrant A., Rodhain J., Cauwe F., Cogneau M., Beckers C., Michaux J.L., et al. Assessment of bone marrow and splenic erythropoiesis in myelofibrosis. Scand J Haematol 1982, 29:373-380.
23. Oshtrakh M.I., Alenkina I.V., Vinogradov A.V., Konstantinova T.S., Kuzmann E., Semionkin V.A. Mossbauer spectroscopy of the iron cores in human liver ferritin, ferritin in normal human spleen and ferritin in spleen from patient with primary myelofibrosis: preliminary results of comparative analysis. Biometals: Int J Role Metal Ions Biol Biochem Med 2013, 26:229-239.
24. Fujiwara T., Ikeda T., Nagasaka Y., Okitsu Y., Katsuoka Y., Fukuhara N., et al. A low-molecular-weight compound K7174 represses hepcidin: possible therapeutic strategy against anemia of chronic disease. PLOS ONE 2013, 8:e75568.
25. Mesa R.A., Shields A., Hare T., Erickson-Viitanen S., Sun W., Sarlis N.J., et al. Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res 2013, 37:911-916.
26. Cheng P.P., Sun Z.Z., Jiang F., Tang Y.T., Jiao X.Y. Hepcidin expression in patients with acute leukaemia. Eur J Clin Investig 2012, 42:517-525.